<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45313">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02022826</url>
  </required_header>
  <id_info>
    <org_study_id>MA-501</org_study_id>
    <nct_id>NCT02022826</nct_id>
  </id_info>
  <brief_title>Clinical Management With SPM System and Validation of the SPM 5 Hour Cutoff in Patients With Symptoms of Gastroparesis</brief_title>
  <official_title>Clinical Management With SmartPill Motility Monitoring System and Validation of the SmartPill Five Hour Cutoff in Patients With Symptoms of Gastroparesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Given Imaging Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Given Imaging Ltd.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol is designed to validate use of the SPM for diagnosis of delayed gastric
      emptying in patients with symptoms of gastroparesis and assess impact of a SmartPill study
      on patient management in the gastroparetic populations.  Patients with symptoms of
      gastroparesis will be recruited.

      Patients will undergo concurrent gastric scintigraphy and SPM testing to determine the
      presence or absence of delayed gastric emptying based on predetermined diagnostic cutoffs
      for each technique.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Per patient device agreement between SmartPill Motility Monitoring System gastric emptying time &amp; gastric Emptying scintigraphy test in patients with symptoms of gastroparesis</measure>
    <time_frame>an expected average of two weeks from study procedure</time_frame>
    <safety_issue>No</safety_issue>
    <description>Per patient device agreement for the diagnosis of delayed gastric emptying between SmartPill Motility Monitoring System (SPM) gastric emptying time (GET &gt;5 hours) and the non-reference standard, gastric Emptying scintigraphy test (&gt;10% retention of a solid meal at 4 hours) in patients with symptoms of gastroparesis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Agreement between Gastric emptying time of SmartPill capsule and gastroduodenal contractility and percent of radiolabeled meal retained at  4 hours on scintigraphy</measure>
    <time_frame>an expected average of two weeks from study procedure</time_frame>
    <safety_issue>No</safety_issue>
    <description>Agreement between Gastric emptying time of SmartPill capsule (GET&gt;8hrs= severe) and gastroduodenal contractility (36)  and percent of radiolabeled meal retained at  4 hours on scintigraphy (&gt;35% = severe)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Gastroparesis</condition>
  <arm_group>
    <arm_group_label>SmartPill Monitoring System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with symptoms of Gastroparesis will undergo the SmartPill monitoring system test</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SmartPill Monitoring System</intervention_name>
    <arm_group_label>SmartPill Monitoring System</arm_group_label>
    <other_name>SPM</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females between ages of 18-80 years of age with symptoms of gastroparesis
             for at least 12 weeks.

          -  Presenting with 2 or more of the following symptoms or signs which, in the opinion of
             the site investigator, are suggestive of a diagnosis of gastroparesis:

               -  1 Nausea, vomiting, or retching (dry heaves)

               -  2 Postprandial fullness or early satiety

               -  3 Bloating or visible abdominal distention

               -  4 Postprandial discomfort or pain

          -  Ability to stop proton pump inhibitors for 7 days and histamine2 receptor
             antagonists, prokinetic agents, narcotic agents, anticholinergic drugs, and
             cannabinoids 3 days prior to SPM and gastric scintigraphy testing.

          -  No evidence of metabolic disease (hypothyroidism, uncontrolled diabetes [hemoglobin
             A1c &gt;10% within the past 6 months], electrolyte imbalance).

          -  An upper endoscopy or upper gastrointestinal barium series within the past 2 years
             showing no organic disease that is potentially causative of symptoms.

          -  High probability of compliance and completion of study.

        Exclusion Criteria:

          -  Participation in previous SmartPill clinical trials.

          -  Previous history of bezoars (the presence of retained liquid, bile, or small amounts
             of poorly organized food residue is permitted).

          -  Dysphagia to solid food or pills.

          -  Prior surgery involving the luminal gastrointestinal tract (cholecystectomy,
             appendectomy, and hysterectomy are permitted if performed &gt; 3 months prior to SPM
             test).

          -  Any abdominal or pelvic surgery within the past 3 months

          -  Known or history of inflammatory bowel disease.

          -  History of diverticulitis, diverticular stricture, and other intestinal strictures.

          -  Chronic daily use of nonsteroidal anti-inflammatory drugs (ibuprofen, naproxen, etc.)

          -  Tobacco or alcohol use within eight hours prior to capsule ingestion.

          -  BMI &gt; 40 kg/m2.

          -  Allergies to eggs, bread, or jam.

          -  Females of childbearing age who are not practicing birth control and/or are pregnant
             or lactating.  (Urine pregnancy testing will be performed on female subjects of
             child-bearing potential prior to capsule ingestion and gastric scintigraphy).

          -  Use of cardiac medical devices such as pacemakers and defibrillators (gastric
             stimulators, bladder stimulators, spinal stimulators, medication infusion devices,
             insulin pumps, continuous glucose monitors are permitted).

          -  Uncontrolled diabetes with a hemoglobin A1c &gt;10%.

          -  Patient is expected to undergo MRI examination within 7 days after ingestion of the
             capsule
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Braden Kuo, Dr.</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_contact>
    <last_name>Braden Kuo, Dr.</last_name>
    <email>bkuo@partners.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Linda Nguyen, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Digestive Health</name>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <zip>33777</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael Schulman, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgia Regents University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Satish S.C. Rao, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>John Wo, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Braden Kuo, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>William Hasler, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Temple University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Henry Parkman, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinsearch,LLC</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Richard Krause, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Tech University</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Richard McCallum, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fletcher Allen Health Care</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Allen Lee, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 21, 2014</lastchanged_date>
  <firstreceived_date>December 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastroparesis</keyword>
  <keyword>SmartPill Monitoring System (SPM)</keyword>
  <keyword>Gastric Emptying Scintigraphy (GES)</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gastroparesis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
